Marszalek M, Karim-Kos H, Madersbacher S, et al. Long term overall survival (OS) in patients with primary metastatic kidney cancer: An analysis of 1468 patients from the Austrian National Cancer Registry (ANCR). EMUC 2017, P113.
FDA keurt pembrolizumab goed voor adjuvante behandeling stadium IIB/IIC-melanoom
dec 2021 | Dermato-oncologie, Immuuntherapie